BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18684496)

  • 1. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
    Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
    Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A; Arnes M; Pettersen I; Larsen K; Hanssen K; Moe B
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
    Arnes M; Hvingel B; Orbo A
    Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.
    Wildemeersch D; Janssens D; Pylyser K; De Wever N; Verbeeck G; Dhont M; Tjalma W
    Maturitas; 2007 Jun; 57(2):210-3. PubMed ID: 17270370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
    Dolapcioglu K; Boz A; Baloglu A
    Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
    Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
    Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
    Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
    Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
    Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
    Giannopoulos T; Butler-Manuel S; Tailor A
    Gynecol Oncol; 2004 Dec; 95(3):762-4. PubMed ID: 15582001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
    El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
    Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
    Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
    Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
    Yuk JS; Song JY; Lee JH; Park WI; Ahn HS; Kim HJ
    Ann Surg Oncol; 2017 May; 24(5):1322-1329. PubMed ID: 27896507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
    Orbo A; Vereide A; Arnes M; Pettersen I; Straume B
    BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.